Previous 10 | Next 10 |
Karyopharm to Participate at the Barclays Global Healthcare Conference PR Newswire NEWTON, Mass. , March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
Gainers: Funko FNKO +16%. Puma Biotechnology PBYI +15%. Duolingo DUOL +15%. Alignment Healthcare ALHC +11%. Veritone VERI +8%. Losers: Smith & Wesson Brands SWBI -15%. Moderna MRNA -6%. Payoneer Global PAYO -4%. Karyopharm Therapeuti...
Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...
The shares of the commercial-stage pharmaceutical company, Karyopharm Therapeutics (NASDAQ:KPTI) have lost ~28% in the pre-market Wednesday amid concerns that the company will need another trial to support its request for U.S. label expansion of cancer therapy, Xpovio (selinexor). F...
Gainers: SoFi Technologies SOFI +20%. Scientific Games Corp SGMS +10%. CytomX Therapeutics CTMX +10%. ZimVie (ZIMV) +9%. PLBY Group PLBY +9%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -27%. HOOKIPA Pharma HOOK -20%. Proterra PTRA -...
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer Following Discussion with the FDA, Karyopharm Plans to Initiate a New Placebo-Controlled Randomized Study of Selinexor in the Advanced or Recurrent Endometrial Cancer p53 Wild-Typ...
Shares of Karyopharm Therapeutics (NASDAQ: KPTI) , a biopharmaceutical company developing new cancer drugs, are tanking Tuesday as investors respond to an unexpected leadership change. The stock was trading 30.5% lower as of 11:52 a.m. ET. On Feb. 8, shares of Karyopharm s...
Gainers: Indonesia (NYSE:INDO) +79%. Meritor (NYSE:MTOR) +45%. Ocugen (NASDAQ:OCGN) +22%. Datasea (NASDAQ:DTSS) +20%. IronNet (NYSE:IRNT) +20%. Riley Exploration Permian (NYSE:REPX) +19%. Arteris (NASDAQ:AIP) +17%. Houghton Mifflin Harcourt Company (NASDAQ:HMHC) +15%. MEDIROM Healthcare Techn...
Gainers: HOOKIPA Pharma HOOK +18%. Nuvectis Pharma (NASDAQ:NVCT) +16%. Ocugen OCGN +14%. Privia Health (NASDAQ:PRVA) +12%. IMARA (NASDAQ:IMRA) +11%. Losers: Allarity Therapeutics (NASDAQ:ALLR) -29%. Homology Medicines FIXX -27%. Karyopharm The...
Homology Medicines (NASDAQ:FIXX) -25% on FDA clinical hold for phenylketonuria trial. Karyopharm Therapeutics (NASDAQ:KPTI) -23% as medical chief steps down. Inspirato (NASDAQ:ISPO) -17%. QIWI (NASDAQ:QIWI) -14%. Yandex (NASDAQ:YNDX) -13%. Energy Vault (NYSE:NRGV) -12%. Ar...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...